

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meetings**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Eunice Kennedy Shriver National Institute of Child Health and Human Development Initial Review Group; Function, Integration, and Rehabilitation Sciences Study Section.

*Date:* October 3, 2023.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2125D, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Moushumi Paul, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2125D, Bethesda, MD 20892, (301) 496-3596, [moushumi.paul@nih.gov](mailto:moushumi.paul@nih.gov).

*Name of Committee:* Eunice Kennedy Shriver National Institute of Child Health and Human Development Initial Review Group; Reproduction, Andrology, and Gynecology Study Section.

*Date:* October 26, 2023.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852.

*Contact Person:* Jagpreet Singh Nanda, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2121C, Bethesda, MD 20892, (301) 451-4454, [jagpreet.nanda@nih.gov](mailto:jagpreet.nanda@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: August 28, 2023.

**Tyeshia M. Roberson-Curtis,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-18939 Filed 8-31-23; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIH Mission Statement**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Request for information.

**SUMMARY:** This Notice is a Request for Information (RFI) inviting feedback on a proposed update to the National Institutes of Health (NIH) mission statement. As the largest public funder of biomedical and behavioral research in the world, NIH works to turn scientific discoveries into better health for all. This RFI will inform NIH's efforts to update its mission statement to ensure that it reflects the NIH mission as accurately as possible. Review of this entire RFI notice is encouraged to ensure your response is comprehensive and to have a full understanding of how it will be used.

**DATES:** Comments must be received by 11:59:59 p.m. (ET) on November 24, 2023 to ensure consideration. After the public comment period has closed, the comments received will be considered in a timely manner by NIH.

**ADDRESSES:** All comments must be submitted electronically on the submission website at <https://rfi.grants.nih.gov/?s=64caaa8bb112e46ad0a1d52>. Responses to this RFI are voluntary and may be submitted anonymously. Please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. The Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part

of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information.

We look forward to your input and hope that you will share this RFI opportunity with your colleagues.

**FOR FURTHER INFORMATION CONTACT:** Questions about this RFI should be directed to Lauren Brodd, Ph.D., Office of the Director, National Institutes of Health, [RFIMissionStatement@nih.gov](mailto:RFIMissionStatement@nih.gov), 301-827-5152.

**SUPPLEMENTARY INFORMATION:** NIH is the nation's medical research agency — making important discoveries that improve health and save lives. NIH's current mission statement at <https://www.nih.gov/about-nih/what-we-do/mission-goals> is “to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.”

In 2021, NIH established the Advisory Committee to the Director (ACD) Working Group on Diversity, Subgroup on Individuals with Disabilities (<https://www.acd.od.nih.gov/working-groups/disabilitiessubgroup.html>) to dedicate time and resources to identify strategies to support individuals with disabilities. The Subgroup issued a report ([https://acd.od.nih.gov/documents/presentations/12092022\\_WGD\\_Disabilities\\_Subgroup\\_Report.pdf](https://acd.od.nih.gov/documents/presentations/12092022_WGD_Disabilities_Subgroup_Report.pdf)) in December 2022 that contains several recommendations, including updating the NIH mission statement. The ACD adopted the Working Group's recommendations and provided them to the NIH Director. The report stated: “One immediate action for the NIH to support disability inclusion is to remove the language of ‘reducing disability’ from the NIH mission statement. The current mission statement could be interpreted as perpetuating ableist beliefs that disabled people are flawed and need to be ‘fixed’.”

To address this suggestion, NIH Leadership committed to evaluate the mission statement, particularly reviewing the inclusion of the phrase “reduce [ . . . ] disability”, and to update it to better reflect the current and future vision for the agency. Following discussions among NIH Leadership and with NIH subject matter experts, a proposed revised mission statement was developed.

**Information Requested**

This RFI invites input from interest groups throughout the scientific

research, advocacy, and clinical practice communities, those employed by NIH or at institutions receiving NIH support, and the public, on a proposed revised mission statement. The bolded language reflects differences between the current and proposed mission statements.

- *Current mission statement*: “To seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.”

- *Proposed revised mission statement*: “To seek fundamental knowledge about the nature and behavior of living systems and to apply that knowledge to optimize health and prevent or reduce illness for all people.”

Input sought about the proposed revised mission statement includes, but is not limited to, the following:

- Feedback on whether the proposed new mission statement reflects the goals and objectives as outlined in the NIH-Wide Strategic Plan for Fiscal Years 2021–2025 (<https://www.nih.gov/sites/default/files/about-nih/strategic-plan-fy2021-2025-508.pdf>).

- Suggestions for specific language that could be added to the proposed mission statement and why.

- Feedback on any specific language that could be removed from the proposed mission statement and why.

NIH encourages organizations (*e.g.*, patient advocacy groups, professional societies) to submit a single response reflective of the views of the organization or its membership.

Dated: August 29, 2023.

**Tara A. Schwetz,**

*Acting Principal Deputy Director, National Institutes of Health.*

[FR Doc. 2023–18989 Filed 8–31–23; 8:45 am]

**BILLING CODE 4140–01–P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Fiscal Year (FY) 2023 Notice of Supplemental Funding Opportunity

**AGENCY:** Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

**ACTION:** Notice of intent to award supplemental funding.

**SUMMARY:** This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting supplemental funding in the scope of the parent award

to the 36 Rural Emergency Medical Services Training Grant (REMS) recipients funded under Notice of Funding Opportunity (NOFO) TI–23–011. These recipients have a project end date of September 29, 2024. The supplemental funding is to provide the opioid antagonist medication, naloxone, that can be used to treat respiratory depression in suspected opioid overdose patients, and for the procurement of emergency equipment used to rapidly reverse the effects of opioid overdoses. Recipients may receive up to \$49,000 for the purchase of naloxone and up to \$49,000 for purchasing equipment, for a total of \$98,000 per recipient.

**FOR FURTHER INFORMATION CONTACT:**

Humberto Carvalho, Email: [Humberto.Carvalho@samhsa.hhs.gov](mailto:Humberto.Carvalho@samhsa.hhs.gov), Phone: (240) 276–2974.

**SUPPLEMENTARY INFORMATION:**

*Funding Opportunity Title:* Rural Emergency Medical Services Training TI–23–011.

*Assistance Listing Number:* 93.243.

*Authority:* The REMS Training grants are authorized under Section 330j of the Public Health Service Act, as amended (42 U.S.C. 254c15).

*Justification:* This is not a formal request for application. Assistance will only be provided to the 36 REMS recipients funded in FY 2023 funded under Rural Emergency Medical Services Training Grant Funding Opportunity TI–23–011, based on the receipt of a satisfactory application and associated budget. The purpose of the supplement is to further expand and enhance REMS grant activities; therefore, only current recipients are eligible.

Dated: August 28, 2023.

**Ann Ferrero,**

*Public Health Analyst.*

[FR Doc. 2023–18911 Filed 8–31–23; 8:45 am]

**BILLING CODE 4162–20–P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine or Oral Fluid (Mandatory Guidelines).

**FOR FURTHER INFORMATION CONTACT:**

Anastasia Donovan, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B, Rockville, Maryland 20857; 240–276–2600 (voice); [Anastasia.Donovan@samhsa.hhs.gov](mailto:Anastasia.Donovan@samhsa.hhs.gov) (email).

**SUPPLEMENTARY INFORMATION:**

In accordance with section 9.19 of the Mandatory Guidelines, a notice listing all currently HHS-certified laboratories and IITFs is published in the **Federal Register** during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at <https://www.samhsa.gov/workplace/resources/drug-testing/certified-lab-list>.

The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) using Urine and of the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid.

The Mandatory Guidelines using Urine were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).

The Mandatory Guidelines using Oral Fluid were first published in the **Federal Register** on October 25, 2019 (84 FR 57554) with an effective date of January 1, 2020.

The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503